Загрузка...
TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer
Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence sti...
Сохранить в:
| Опубликовано в: : | Cancers (Basel) |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6406945/ https://ncbi.nlm.nih.gov/pubmed/30759864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020210 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|